Zhongxin Jingwei, March 14 - Just this past weekend, the new crown antigen detection kit has become a hot topic in the market. Stimulated by the good news, on March 14, in the context of the decline in the A-share index and about 4200 shares, the relevant concept stocks were particularly active against the market.
As of the close, Yirui Biotech 20% up and down, Nuoweizan, Lanwei Medical, Sanwei Tiandi, Fosun Pharmaceutical intraday have touched the limit, BGI Gene rose as high as more than 16%, Saili Medical, Huachangsheng, Beihua share seal, Pony test, Heatscape Biology, Tianrui Instrument, Wanfu Biology, Lepu Medical and so on have gone higher.
Covid-19 concept stock performance Source: Flush
10 company products have been approved, and the e-commerce platform has been launched for pre-sale
The detection of the new coronavirus is a key step in the prevention and control of the epidemic. On Friday, March 11, it was officially announced that antigen testing would be added to the nucleic acid test as a supplement.
Up to now, the State Food and Drug Administration has approved 10 new crown antigen detection kit products for listing, involving companies including: Beijing Wantai Biological Pharmaceutical Co., Ltd., Beijing Heatscape Biotechnology Co., Ltd., Tianjin Boosaisi Biotechnology Co., Ltd., Chongqing MingdaoJieji Biotechnology Co., Ltd., Beijing Lepu Diagnostic Technology Co., Ltd., Nanjing Novizin Medical Technology Co., Ltd., Beijing Jinwolf Biological Engineering Technology Co., Ltd., Shenzhen Huada Inyuan Pharmaceutical Technology Co., Ltd., Guangzhou Wanfu Biotechnology Co., Ltd., Beijing Huaketai Biotechnology Co., Ltd.
Source: State Food and Drug Administration (March 13)
As can be seen on the introduction page, the new crown antigen self-test kit is "super easy to operate", nasopharyngeal/oropharyngeal sampling can be completed by individuals, and the test results can be obtained in 10-20 minutes.
Source: Taobao, Jingdong APP
Among them, Taobao's first batch of pre-issued antigen detection kits are Nuoweizan antigen detection kits, with a specification of 20 people / box, priced at 486 yuan, shipped within four days after payment, and currently sold 1000+. There are also Wanfu and Jinwolf antigen detection kits "stay tuned", which cannot be clicked to enter the detailed page.
For "delivery within 4 days after payment", Mr. Gao, a regional sales officer of Nuoweizan, told "VGuan Financial Report" that "it cannot be guaranteed, and the specific delivery time needs to wait for the company's notice". For the purchase channel, Mr. Gao said that the channel must be qualified, and there are not many external authorizations at present.
Jingdong Health pre-sold antigen detection kits of Heatscape Biology, Jinwolf, Novizon and BGI Gene, the product prices of the first two brands are "to be released", and the prices of the last two brands are 486 yuan (20 servings) and 490 yuan (20 servings) respectively. There are also antigen detection kits of Lepu, Wantai and Wanfu (two specifications) "Stay tuned".
Source: Suning Tesco, Meituan APP
Suning Tesco and Novizan cooperated to launch the antigen detection test kit, the specification is 20 people / part, the price is 459 yuan, the expected delivery time is March 20. Meituan bought the drug on the shelves for Beijing Jinwolf new crown antigen self-testing agent box, the price is 32.8 yuan (1 person), is expected to be shipped in about 15 days.
"VGuan Financial Report" checked the announcements of listed companies and found that Wantai Biology, Heatscape Biology, Lepu Medical, Nuoweizan, BGI Gene, and Wanfu Biology did not explicitly mention the partners in the existing announcements.
According to incomplete statistics of public information, Wantai Bio said that it reached a cooperation with Jingdong Health on March 13. Meinian Health signed a strategic cooperation agreement with Heatscape Biologics to become the core partner of its sales channels for new crown antigen testing products. BGI signed cooperation agreements with 8 companies on the new crown antigen test kit, of which 1 drug network is the only online platform.
However, Wanfu Biotech has issued a statement twice a few days ago that the antigen detection kit developed by the company has changed the medical device approval documents, and now it is found that some individuals and companies have carried out illegal sales publicity through e-commerce and other online channels without the company's legal authorization. The Company has not yet entered into a sales agreement with the commercial retail OTC channel for the product, nor has it sold such a product.
Institutions: The monthly market size exceeds 10 billion
New crown antigen self-test products listed, how about the domestic market?
Zheshang Securities previously introduced in the research report that compared with the current nucleic acid testing, on the one hand, antigen self-testing can save the cost of instruments, sites, labor and other costs of nucleic acid testing, and the current price of new crown nucleic acid mixed testing ranges from 20-40 yuan, which is significantly higher than the terminal price of antigen self-testing agent boxes in the current European market; on the other hand, it helps to classify and divert the new crown detection, avoid the waste of medical resources caused by the unified use of nucleic acids, and alleviate the shortage of testing resources in the centralized testing demand scenario.
Guolian Securities said that after antigen detection as a supplementary means, it is expected that there will be applications in scenarios such as rapid screening in personnel gathering scenarios, community home detection, and grass-roots detection of symptomatic people, based on the consideration of supply security and price accessibility, domestic new crown drugs are worth looking forward to.
Soochow Securities believes that antigen detection is applicable to the incubation period and acute stage, which is of great significance for early detection, the accuracy of domestic new crown antibody detection has been verified overseas, and the future self-test of new crown antigen is expected to be widely promoted in China.
Pacific Securities bluntly said, "The market space is huge." In the latest research report, Pacific Securities estimates that Germany provides free antigen testing services at most once a day during the peak of the epidemic, and other overseas countries issue about 2-10 antigen self-test products per month, and the unit price of domestic manufacturers is 0.7-2 US dollars. According to the peak period of 1-2 per capita testing frequency per month, the factory unit price of 8-12 yuan, the total population of 1.4 billion, the domestic antigen self-test month market size reached 11.2-33.6 billion yuan.
Dongguan Securities also believes that the new crown antigen test has the advantages of timeliness, low conditions for development, and price, and with the gradual liberalization of epidemic prevention and control policies, antigen testing is expected to be widely applied in China, and the market space is vast.
Everbright Securities also reminded that attention should be paid to the domestic antigen self-testing market after the policy is implemented, antigen detection has the advantages of high efficiency, speed and low cost, and China's antigen detection market of 10 billion is about to be opened. (Zhongxin Jingwei APP)
(The views in this article are for reference only and do not constitute investment advice, investment is risky, and you need to be cautious when entering the market.) )
Zhongxin Jingwei copyright, without written authorization, any unit and individual shall not reprint, excerpt or otherwise use.